RJA
LLY icon

Raymond James & Associates’s Eli Lilly LLY Stock Holding History

Raymond James & Associates’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$974M Buy
1,099,584
+75,280
+7% +$67.7M 0.59% 26
2024
Q2 		$927M Buy
1,024,304
+88,549
+9% +$70.8M 0.61% 25
2024
Q1 		$728M Buy
935,755
+69,253
+8% +$49.3M 0.49% 33
2023
Q4 		$505M Buy
866,502
+69,101
+9% +$40.3M 0.38% 49
2023
Q3 		$428M Sell
797,401
-22,232
-3% -$11.5M 0.36% 51
2023
Q2 		$384M Buy
819,633
+65,262
+9% +$27.4M 0.32% 60
2023
Q1 		$259M Buy
754,371
+66,003
+10% +$22.3M 0.23% 81
2022
Q4 		$252M Buy
688,368
+33,406
+5% +$11.8M 0.23% 82
2022
Q3 		$212M Sell
654,962
-21,271
-3% -$6.74M 0.21% 89
2022
Q2 		$219M Sell
676,233
-24,283
-3% -$7.29M 0.21% 89
2022
Q1 		$201M Buy
700,516
+16,021
+2% +$4.12M 0.17% 109
2021
Q4 		$189M Buy
684,495
+42,734
+7% +$10.8M 0.15% 126
2021
Q3 		$148M Sell
641,761
-108,538
-14% -$26.8M 0.13% 145
2021
Q2 		$172M Buy
750,299
+75,389
+11% +$15.1M 0.16% 121
2021
Q1 		$126M Buy
674,910
+12,770
+2% +$2.5M 0.13% 145
2020
Q4 		$112M Sell
662,140
-48,230
-7% -$7.2M 0.12% 147
2020
Q3 		$105M Sell
710,370
-41,652
-6% -$6.45M 0.13% 141
2020
Q2 		$123M Sell
752,022
-39,569
-5% -$6.07M 0.17% 112
2020
Q1 		$110M Buy
791,591
+104,467
+15% +$14.4M 0.17% 99
2019
Q4 		$90.3M Buy
687,124
+7,338
+1% +$851K 0.11% 156
2019
Q3 		$76M Buy
679,786
+229,421
+51% +$25.5M 0.11% 177
2019
Q2 		$49.9M Sell
450,365
-64,977
-13% -$7.65M 0.07% 254
2019
Q1 		$66.9M Sell
515,342
-5,852
-1% -$712K 0.1% 196
2018
Q4 		$60.3M Buy
521,194
+68,996
+15% +$7.71M 0.11% 179
2018
Q3 		$48.5M Buy
452,198
+17,283
+4% +$1.73M 0.08% 237
2018
Q2 		$37.1M Buy
434,915
+51,504
+13% +$4.23M 0.06% 289
2018
Q1 		$29.7M Sell
383,411
-9,180
-2% -$739K 0.05% 340
2017
Q4 		$33.2M Buy
392,591
+27,463
+8% +$2.34M 0.06% 290
2017
Q3 		$31.2M Buy
365,128
+9,701
+3% +$796K 0.06% 292
2017
Q2 		$29.3M Sell
355,427
-24,400
-6% -$1.99M 0.06% 297
2017
Q1 		$31.9M Sell
379,827
-32,574
-8% -$2.61M 0.07% 264
2016
Q4 		$30.3M Buy
412,401
+194
+0% +$14.4K 0.08% 254
2016
Q3 		$33.1M Buy
412,207
+109,755
+36% +$8.78M 0.09% 221
2016
Q2 		$23.8M Buy
302,452
+27,167
+10% +$2.05M 0.07% 272
2016
Q1 		$19.8M Sell
275,285
-32,621
-11% -$2.47M 0.07% 307
2015
Q4 		$25.9M Buy
307,906
+12,581
+4% +$1.04M 0.09% 239
2015
Q3 		$24.7M Buy
295,325
+8,377
+3% +$707K 0.1% 223
2015
Q2 		$24M Buy
286,948
+61,590
+27% +$4.69M 0.09% 251
2015
Q1 		$16.4M Buy
225,358
+14,831
+7% +$1.06M 0.07% 297
2014
Q4 		$14.5M Sell
210,527
-224,510
-52% -$15.2M 0.07% 302
2014
Q3 		$28.2M Buy
435,037
+103,973
+31% +$6.58M 0.16% 119
2014
Q2 		$20.6M Buy
331,064
+30,703
+10% +$1.83M 0.13% 180
2014
Q1 		$17.7M Buy
300,361
+13,617
+5% +$760K 0.12% 185
2013
Q4 		$14.6M Sell
286,744
-51,102
-15% -$2.56M 0.11% 201
2013
Q3 		$17M Sell
337,846
-8,394
-2% -$439K 0.15% 137
2013
Q2 		$17M Buy
+346,240
New +$18.8M 0.16% 125

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Raymond James & Associates's LLY Position: Q3 2024 in Review

Raymond James & Associates increased its Eli Lilly (LLY) stake by 7.3% in Q3 2024, buying an estimated $67.7M and bringing the position to 1,099,584 shares worth $974M. The position accounts for 0.59% of the portfolio, ranked #26.

Raymond James & Associates first reported a position in LLY in Q2 2013 and has held it in 46 quarters since. 3,657 funds tracked by Wall St. Rank hold LLY as of Q3 2024.

  • Raymond James & Associates held 1,099,584 shares of Eli Lilly worth $974M as of Q3 2024.
  • Raymond James & Associates bought 75,280 Eli Lilly shares in Q3 2024, an estimated $67.7M.
  • Eli Lilly made up 0.59% of Raymond James & Associates's portfolio in Q3 2024, its #26 holding.
  • Raymond James & Associates first reported a position in Eli Lilly in Q2 2013 and has held it in 46 quarters since.
  • 3,657 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.